Peroxisome proliferator-activated receptor-gamma agonist inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation

Genes and Immunity

Volumn 3, Issue 2, 2002, Pages 59-70

  Natarajan, C ^a   Bright, John J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokine; Immunomodulation; Inflammation; Signal transduction; Th1 cells

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; CELL NUCLEUS ANTIGEN; CELL NUCLEUS RECEPTOR; CIGLITAZONE; GLUCOSE; INTERLEUKIN 12; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR; 15 DEOXY DELTA(12,14) PROSTAGLANDIN J2; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; BIOLOGICAL RESPONSE MODIFIER; CELL RECEPTOR; DNA BINDING PROTEIN; DRUG DERIVATIVE; JAK2 PROTEIN, HUMAN; JAK2 PROTEIN, MOUSE; JANUS KINASE 2; MYELIN BASIC PROTEIN; ONCOPROTEIN; PROSTAGLANDIN D2; PROTEIN TYROSINE KINASE; THIAZOLE DERIVATIVE;

ACTIVE IMMUNIZATION; ADIPOCYTE; ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMYELINATING DISEASE; DISEASE SEVERITY; DRUG POTENCY; FEMALE; GLUCOSE HOMEOSTASIS; IMMUNOPATHOGENESIS; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; MOUSE; MULTIPLE SCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH1 CELL; ANIMAL; BIOSYNTHESIS; CELL CULTURE; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; IMMUNOLOGY; KINETICS; LYMPHOCYTE ACTIVATION; MACROPHAGE; METABOLISM; MICROGLIA; PATHOLOGY; SPINAL CORD;

ANIMALIA;

ANIMALS; BIOLOGICAL RESPONSE MODIFIERS; CELL DIFFERENTIATION; CELLS, CULTURED; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; INTERLEUKIN-12; JANUS KINASE 2; KINETICS; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICE; MICROGLIA; MYELIN BASIC PROTEINS; PROSTAGLANDIN D2; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; SPINAL CORD; TH1 CELLS; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0036546185     PISSN: 14664879     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gene.6363832     Document Type: Article

References (60)

1. Evans RM. The steroid and thyroid hormone receptor super-family. Science 1988; 240: 889-895.
2. Blumberg B, Evans RM. Orphan nuclear receptors: new ligands and new possibilities. Genes Dev 1998; 12: 3149-3155.
3. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-688.
4. Elbrecht A, Chen Y, Cullinan CA et al. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem Biophys Res Commun 1996; 224: 431-437.
5. Mukherjee R, Jow L, Croston GE, Paterniti JR. Identification, characterization and tissue distribution of human peroxisome proliferator activated receptor isoforms 1 and 2 and activation with retinoid x receptor agonists and antagonists. J Biol Chem 1997; 272: 18779-18789.
6. Barak Y, Nelson MC, Ong ES et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999; 4: 585-595.
7. Willson TM, Wahli W. Peroxisome proliferator activated receptor agonists. Corr Opin Chem Biol 1997; 1: 235-241.
8. Krey G, Braissant O, Horset FL et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 1997; 11: 779-791.
9. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman B, Evans RM. 15-Deoxy-12,14 prostaglandin J2 a ligand for the adipocyte determination factor PPAR. Cell 1995; 83: 803-812.
10. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARγ . J Biol Chem 1995; 270: 12953-12956.
11. Shao D, Rangwala SM, Bailey ST, Krakow SL, Reginato MJ, Lazar MA. Interdomain communication regulating ligand binding by PPARγ. Nature 1998; 396: 377-380.
12. Palmer CN, Hsu MH, Griffin HJ, Johnson EF. Novel sequence determinants in peroxisome proliferator signaling. J Biol Chem 1995; 270: 16114-16121.
13. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992; 358: 771-774.
14. Kliewer SA, Willson TM. The nuclear receptor PPAR-bigger than fat. Curr Opin Genet Dev 1998; 8: 576-581.
15. Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. N Engl J Med 1998; 338: 861-866.
16. Barroso I, Gurnell M, Crowley VE et al. Dominant negative mutations in human PPAr gamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402: 880-883.
17. Demetri GD, Fletcher CD, Mueller E et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 1999; 196: 3951-3956.
18. Elstner E, Muller C, Koshizuka K et al. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998; 95: 8806-8811.
19. Asou H, Verbeek W, Williamson E et al. Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids. Int J Oncol 1999; 15: 1027-1037.
20. Tsubouchi Y, Sano H, Kawahito Y et al. Inhibition of human lung cancer cell growth by the PPARγ agonists through induction of apoptosis. Biochem Biophys Res Commun 2000; 270: 400-405.
21. Sarraf P, Mueller E, Smith WM et al. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell 1999; 3: 799-804.
22. Sarraf P, Mueller E, Jones D et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998; 4: 1046-1052.
23. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
24. Jiang C, Ting AT, Seed B. PPARγ agonists inhibit production of monocyte inflammatory cytokine. Nature 199; 391: 82-86.
25. Kawahito Y, Kondo M, Tsubouchi Y et al. 15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 2000; 106: 189-197.
26. Neve BP, Fruchart JC, Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol 2000; 60: 1245-1250.
27. Chen Z, Ishibashi S, Perrey S et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 2001; 21: 372-377.
28. Su CG, Wen X, Bailey ST et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999; 104: 383-389.
29. Pershadsingh HA, Sproul JA, Benjamin E, Finnegan J, Amin NM. Treatment of psoriasis with troglitazone therpay. Arch Dermatol 1998; 134: 1304-1305.
30. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998; 93: 229-40.
31. Spiegelman BM. PPARγ in monocytes-less pain, any gain? Cell 1998; 93: 153-155.
32. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 2000; 164: 1364-1371.
33. Harris SG, Phipps RP. The nuclear receptor PPAR gamma is expressed by mouse T lymphocytes and PPAR gamma agonists induce apoptosis. Eur J Immunol 2001; 4: 1098-1105.
34. Dean G. How many people in the world have MS? Neuroepidemiology 1994; 13: 1-7.
35. Clegg A, Bryant J. Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness. Expert Opin Pharmacother 2001; 2: 623-639.
36. Wingerchuk DM, Lucchinetti CF, Noseworthy JH. Multiple sclerosis: current pathophysiological concepts. Lab Invest 2001; 81: 263-281.
37. Raine CS. The Dale McFarlin lecture: Immunology of the MS lesion. Ann Neurol 1994; 36: 61-72.
38. Martin R, McFarland HF, McFarlin DE. Immunology of demyelinating disease. Annu Rev Immunol 1992; 10: 153-169.
39. O'Connor KC, Bar-Or A, Hafler DA. The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. J Clin Immunol 2001; 21: 81-92.
40. Gold R, Hartung HP, Toyka KV. Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today 2000; 6: 88-91.
41. Xiao BG, Link H. Antigen-specific T cells in autoimmune diseases with a focus on multiple sclerosis and experimental allergic encephalomyelitis. Cell Mol Life Sci 1999; 56: 5-21.
42. Owens T, Sriram S. The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis. Neurol Clin 1995; 13: 51-73.
43. Bettelli E, Nicholson E. The role of cytokines in experimental autoimmune encephalomyelitis. Arch Immunol Ther Exp 2000; 48: 389-398.
44. Trinchieri G. Interleukin 12: a pro-inflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen specific adaptive immunity. Annu Rev Immunol 1995; 13: 247-251.
45. Bright JJ, Musuro BF, Du C, Sriram S. Expression of IL-12 in CNS and lymphoid organs of mice with experimental allergic encephalomyelitis. J Neuroimmunol 1998; 82: 22-30.
46. Bright JJ, Rodriguez M, Sriram S. Differential influence of interleukin-12 in the pathogenesis of autoimmune and virus-induced CNS demyelination. J Virol 1999; 73: 1637-1639.
47. Karp CL. Interleukin-12: amiss in MS. Ann Neurol 1999; 45: 689-692.
48. Leonard JP, Waldburger KE, Goldman SJ. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin-12. J Exp Med 1995; 181: 381-386.
49. Bright JJ, Du C, Coon M, Sriram S, Klaus SJ. Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signaling and IL-12-mediated Th1 differentiation: an effect of the novel anti-inflammatory drug lisofylline. J Immunol 1998; 161: 7015-7022.
50. Bright JJ, Du C, Sriram S. Tyrphostin B42 inhibits IL-12-induced tyrosine phosphorylation and activation of Janus kinase-2 and prevents experimental allergic encephalomyelitis. J Immunol 1999; 162: 6255-6262.
51. Chung SW, Kang BY, Kim SH et al. Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B. J Biol Chem 2000; 275: 32681-32687.
52. Murphy TL, Cleveland MG, Kulesza P, Magram J, Murphy KM. Regulation of interleukin 12 p40 expression through an NF-kappa B half-site. Mol Cell Biol 1995; 15: 5258-5267.
53. Crabtree GR. Contingent genetic regulatory events in T lymphocyte activation. Science 1989; 243: 355-361.
54. Bacon CM, Petricoin III EF, Ortaldo JR, Rees RC, Larner AC, Johnston JA, O'Shea JJ. Interleukin 12 induces tyrosine phosphorylation and activation of Stat 4 in human lymphocytes. Proc Natl Acad Sci USA 1995; 92: 7307-7311.
55. Jacobson NG, Szabo SJ, Weber-Nordt RM et al. Interleukin-12 signaling in Th1 cells involves tyrosine phosphorylation of Stat3 and Stat4. J Exp Med 1995; 181: 1755-1762.
56. Bright JJ, Sriram S. TGF-beta inhibits IL-12-induced activation of Jak-STAT pathway in T lymphocytes. J Immunol 1998; 161: 1772-1777.
57. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPARγ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001; 7: 48-52.
58. Bright JJ, Kerr LD, Sriram S. TGF-beta inhibits IL-2-induced tyrosine phosphorylation and activation of Jak1 and Stat5 in T lymphocytes. J Immunol 1997; 159: 175-183.
59. Du C, Bright JJ, Sriram S. Inhibition of CD40 signaling pathway by tyrphostin A1 reduces secretion of IL-12 in macrophage Th1 cell development and experimental allergic encephalomyelitis in SJL/J mice. J Neuroimmunol 2001; 114: 69-79.
60. Walker WS, Gatewood J, Olivas E, Askew D, Havenith CE. Mouse microglial cell lines differing in constitutive and interferon-gamma-inducible antigen-presenting activities for naive and memory CD4+ and CD8+ T cells. J Neuroimmunol 1995; 63: 163-174.